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Keeping pace with emerging evidence is an ongoing chal-
lenge to timely development of clinical practice guidelines.
In an effort to respond promptly to new evidence, the Amer-
ican College of Cardiology (ACC)/American Heart Associ-
ation (AHA)Task Force on PracticeGuidelines (Task Force)
has created a ‘‘focused update’’ process to revise the existing
guideline recommendations that are affected by evolving
data or opinion. New evidence is reviewed in an ongoinge6 The Journal of Thoracic and Cardiovascular Surgemanner to respond quickly to important scientific and treat-
ment trends that could have a major impact on patient out-
comes and quality of care. Evidence is reviewed at least
twice a year, and updates are initiated on an as-needed basis
and completed as quickly as possible while maintaining the
rigorous methodology that the ACC and AHA have devel-
oped during their partnership of>20 years.
A focused update is initiated when new data that are
deemed potentially important for patient care are published
or presented at national and international meetings (Section
1.1, ‘‘Methodology and Evidence Review’’). Through a
broad-based vetting process, the studies included are iden-
tified as being important to the relevant patient population.
The focused update is not intended to be based on a com-
plete literature review from the date of the previous guide-
line publication but rather to include pivotal new evidence
that may effect changes in current recommendations. Spe-
cific criteria or considerations for inclusion of new data
include the following:
 Publication in a peer-reviewed journal;
 Large, randomized, placebo-controlled trial(s);
 Nonrandomized data deemed important on the basis of
results affecting current safety and efficacy assumptions,
including observational studies and meta-analyses;
 Strength/weakness of research methodology and findings;
 Likelihood of additional studies influencing current find-
ings;
 Impact on current performance measures and/or likeli-
hood of need to develop new performance measure(s);
 Request(s) and requirement(s) for review and update from
the practice community, key stakeholders, and other sour-
ces free of industry relationships or other potential bias;
 Number of previous trials showing consistent results; and
 Need for consistency with a new guideline or guideline
updates or revisions.
In analyzing the data and developing recommendations
and supporting text, a writing committee uses evidence-
based methodologies developed by the Task Force.1 The
Class of Recommendation (COR) is an estimate of the
size of the treatment effect, with consideration given to risks
versus benefits as well as evidence and/or agreement that a
given treatment or procedure is or is not useful/effective and
in some situations may cause harm. The Level of Evidence
(LOE) is an estimate of the certainty or precision of the
treatment effect. The writing committee reviews and ranks
evidence supporting each recommendation, with the weight
of evidence ranked as LOE A, B, or C, according to specific
definitions that are included in Table 1. Studies are identi-
fied as observational, retrospective, prospective, or random-
ized as appropriate. For certain conditions for which
inadequate data are available, recommendations are based
on expert consensus and clinical experience and are ranked
as LOE C. When recommendations at LOE C are supportedry c March 2015
TABLE 1. Applying classification of recommendations and level of evidence
A recommendation with Level of Evidence B or C does not imply that the recommendation is weak. Many important clinical questions addressed in the guidelines do not lend
themselves to clinical trials. Although randomized trials are unavailable, there may be a very clear clinical consensus that a particular test or therapy is useful or effective. *Data
available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes mellitus, history of prior myocardial infarc-
tion, history of heart failure, and prior aspirin use. yFor comparative-effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use
of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated.
Fihn et al Clinical Guidelinesby historical clinical data, appropriate references (including
clinical reviews) are cited if available. For issues about
which sparse data are available, a survey of current practice
among the clinicians on the writing committee is the basis
for LOE C recommendations, and no references are cited.
The schema for COR and LOE is summarized in Table 1,
which also provides suggested phrases for writing recom-
mendations within each COR. A new addition to this meth-
odology is separation of the Class III recommendations to
delineate whether the recommendation is determined to
be of ‘‘no benefit’’ or is associated with ‘‘harm’’ to theThe Journal of Thoracic and Cpatient. In addition, in view of the increasing number of
comparative-effectiveness studies, comparator verbs and
suggested phrases for writing recommendations for the
comparative effectiveness of one treatment or strategy
versus another have been added for COR I and IIa, LOE
A or B only.
In view of the advances in medical therapy across the
spectrum of cardiovascular diseases, the Task Force has
designated the term guideline-directed medical therapy
(GDMT) to represent medical therapy that is strongly rec-
ommended by (primarily Class I and IIa) ACC/AHAardiovascular Surgery c Volume 149, Number 3 e7
Clinical Guidelines Fihn et alguidelines. The term, GDMT, will be used herein. It is antic-
ipated that what currently constitutes GDMT will evolve
over time as new therapies and evidence emerge.
Because the ACC/AHA practice guidelines address pa-
tient populations (and healthcare providers) residing in
North America, drugs that are currently unavailable in
North America are discussed in the text without a specific
COR. For studies performed in large numbers of subjects
outside North America, a writing committee reviews the po-
tential impact of different practice patterns and patient pop-
ulations on the treatment effect and relevance to the ACC/
AHA target population to determine whether the findings
should inform a specific recommendation.
The ACC/AHA practice guidelines are intended to assist
healthcare providers in clinical decision making by
describing a range of generally acceptable approaches to
the diagnosis, management, and prevention of specific dis-
eases or conditions. The guidelines are intended to define
practices that meet the needs of most patients in most cir-
cumstances. The ultimate judgment about care of a partic-
ular patient must be made by the healthcare provider and
patient in light of all the circumstances presented by that pa-
tient. As a result, situations may arise in which deviations
from these guidelines are appropriate. In clinical decision
making, consideration should be given to the quality and
availability of expertise in the area where care is provided.
When these guidelines are used as the basis for regulatory or
payer decisions, the goal should be improvement in quality
of care.
Prescribed courses of treatment in accordance with these
recommendations are effective only if they are followed.
Because lack of patient understanding and adherence may
adversely affect outcomes, physicians and other healthcare
providers should engage the patient’s active participation in
prescribed medical regimens and lifestyles. In addition, pa-
tients should be informed of the risks and benefits of and al-
ternatives to a particular treatment and should be involved
in shared decision making whenever feasible, particularly
for COR IIa and IIb, for which the benefit-to-risk ratio
may be lower.
The Task Force makes every effort to avoid actual, poten-
tial, or perceived conflicts of interest that may arise as a
result of industry relationships, professional biases, or per-
sonal interests among the members of the writing group. All
writing committee members and peer reviewers of the
guideline are required to disclose all current healthcare–
related relationships, including those existing 12 months
before initiation of the writing effort. In December 2009,
the ACC and AHA implemented a new policy for relation-
ships with industry and other entities (RWI) that requires
the writing committee chair plus a minimum of 50% of
the writing committee to have no relevant RWI
(Appendix 1 for the ACC/AHA definition of relevance).
These statements are reviewed by the Task Force and alle8 The Journal of Thoracic and Cardiovascular Surgemembers during each conference call and/or meeting of
the writing committee and are updated as changes occur.
All guideline recommendations require a confidential vote
by the writing committee and must be approved by a
consensus of the voting members. Members are not
permitted to draft or vote on any text or recommendations
pertaining to their RWI. Members of this writing group,
who recused themselves from voting, are indicated, and
specific section recusals are noted in Appendix 1. Authors’
and peer reviewers’ RWI pertinent to this guideline are dis-
closed in Appendices 1 and 2, respectively. Additionally, to
ensure complete transparency, this writing group members’
comprehensive disclosure information—including RWI not
pertinent to this document—is available as an Online
supplement. Comprehensive disclosure information for
the Task Force is also available online. The work of this
writing group is supported exclusively by the ACC, AHA,
American Association for Thoracic Surgery (AATS),
Preventive Cardiovascular Nurses Association (PCNA),
Society for Cardiovascular Angiography and Interventions
(SCAI), and Society of Thoracic Surgeons (STS) without
commercial support. Writing group members volunteered
their time for this activity.
To maintain relevance at the point of care for practicing
physicians, the Task Force continues to oversee an ongoing
process improvement initiative. As a result, in response to
pilot projects, several changes to these guidelines will be
apparent, including limited narrative text and a focus on
summary and evidence tables (with references linked to ab-
stracts in PubMed).
In April 2011, the Institute of Medicine released 2 re-
ports: Finding What Works in Health Care: Standards for
Systematic Reviews and Clinical Practice Guidelines We
Can Trust.2,3 It is noteworthy that the ACC/AHA practice
guidelines were cited as being compliant with many of
the standards that were proposed. A thorough review of
these reports and our current methodology is under way,
with further enhancements anticipated.
The recommendations in this focused update are consid-
ered current until they are superseded in another focused
update or the full-text guideline is revised. Guidelines are
official policy of the ACC and AHA.
Jeffrey L. Anderson, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. INTRODUCTION
These guidelines are intended to apply to adult patients
with stable known or suspected ischemic heart disease
(IHD), including those with new-onset chest pain (ie,
low-risk unstable angina) or stable pain syndromes. Pa-
tients who have ‘‘ischemic equivalents,’’ such as dyspnea
or arm pain with exertion, are included in the latter group.
Many patients with IHD may become asymptomatic with
appropriate therapy. Accordingly, the follow-up sectionsry c March 2015
Fihn et al Clinical Guidelinesof this guideline pertain to patients who were previously
symptomatic, including those who have undergone percu-
taneous coronary intervention (PCI) or coronary artery
bypass graft (CABG). In this document, ‘‘coronary angi-
ography’’ is understood to refer to invasive coronary
angiography.
1.1. Methodology and Evidence Review
Late-breaking clinical trials presented at the 2012 scien-
tific meetings of the ACC, AHA, and European Society of
Cardiology, as well as other selected data reported through
October, 2013, were reviewed by the 2012 stable ischemic
heart disease (SIHD) guideline writing committee along
with the Task Force and other experts to identify trials
and other key data that might affect guideline recommenda-
tions. On the basis of the criteria and considerations noted
previously (see Preamble), recently published trial data
and other clinical information were considered important
enough to prompt a focused update of the 2012 SIHD guide-
line.4 Evidence considered for deliberation by the writing
group was added to evidence tables in the Data
Supplement available online, although it did not result in
recommendation changes. Among the topics considered
for inclusion in the focused update was the use of fractional
flow reserve (FFR) for assessing intermediate coronary le-
sions, including newer data from the FAME (Fractional
Flow Reserve Vs Angiography for Multivessel Evaluation)
2 study.5 Although this was acknowledged to be an impor-
tant new contribution to the literature, it did not alter the rec-
ommendations for FFR made in the 2012 full-text
guideline.4
Consult the full-text version or the executive summary of
the 2012 SIHD guideline for policy on clinical areas not
covered by the focused update.4,6 The individual
recommendations in this focused update will be
incorporated into future revisions or updates of the full-
text guideline.
1.2. Organization of Committee and Relationships
With Industry
For this focused update, representative members of the
2012 stable ischemic heart disease (SIHD) guideline
writing committee were invited to participate, and they
were joined by additional invited members to form a new
writing group, referred to as the 2014 focused update
writing group. Members were required to disclose all
RWI relevant to the data under consideration. The writing
group included representatives from the ACC, AHA,
AATS, PCNA, SCAI, and STS.
1.3. Review and Approval
This document was reviewed by 5 official reviewers from
the ACC and the AHA, as well as 1 reviewer each from the
AATS, PCNA, SCAI, and STS; and 33 individual contentThe Journal of Thoracic and Creviewers, including members of the American College of
Physicians, ACC Imaging Section Leadership Council,
ACC Interventional Section Leadership Council, ACC Pre-
vention of Cardiovascular Disease Section Leadership
Council, ACC Surgeons’ Council, AHA Council on Clin-
ical Cardiology, and the Association of International Gover-
nors. Reviewers’ RWI information was collected and
distributed to the writing group and is published in this
document (Appendix 2).
This document was approved for publication by the gov-
erning bodies of the ACC, AHA, and by other partner orga-
nizations, the AATS, PCNA, SCAI, and STS.
2. DIAGNOSIS OF SIHD
2.1. Invasive Testing for Diagnosis of Coronary
Artery Disease in Patients With Suspected SIHD:
Recommendations (New Section)
See Online Data Supplement 1 for additional information
Class I
1. Coronary angiography is useful in patients with presumed SIHD
who have unacceptable ischemic symptoms despite GDMT and
who are amenable to, and candidates for, coronary revasculariza-
tion. (Level of Evidence: C)Class IIa
1. Coronary angiography is reasonable to define the extent and
severity of coronary artery disease (CAD) in patients with suspected
SIHD whose clinical characteristics and results of noninvasive
testing (exclusive of stress testing) indicate a high likelihood of severe
IHD and who are amenable to, and candidates for, coronary revas-
cularization.7-12 (Level of Evidence: C)
2. Coronary angiography is reasonable in patients with suspected
symptomatic SIHD who cannot undergo diagnostic stress testing,
or have indeterminate or nondiagnostic stress tests, when there is
a high likelihood that the findings will result in important changes
to therapy. (Level of Evidence: C)Class IIb
1. Coronary angiography might be considered in patients with stress
test results of acceptable quality that do not suggest the presence
of CAD when clinical suspicion of CAD remains high and there is
a high likelihood that the findings will result in important changes
to therapy. (Level of Evidence: C)
This section has been added to the 2014 SIHD
focused update to fill a gap in the 2012 SIHD guide-
line.4 It specifically addresses the role of coronary angi-
ography for the diagnosis of CAD in patients with
suspected SIHD.
Coronary angiography for risk stratification has been ad-
dressed in Section 3.3 of the 2012 SIHD full-text guideline.4
Recommendations for use of coronary angiography in the
following specific clinical circumstances have beenardiovascular Surgery c Volume 149, Number 3 e9
Clinical Guidelines Fihn et aladdressed in other guidelines or statements and will not be
discussed further here:
 Patients with heart failure and/or reduced ejection frac-
tion13
 Patients who have experienced sudden cardiac death or
sustained ventricular arrhythmia14
 Patients undergoing preoperative cardiovascular evalua-
tion for noncardiac surgery (including solid organ trans-
plantation)15
 Evaluation of cardiac disease among patients who are
kidney or liver transplantation candidates16,17
Note that ACC/AHA guidelines for coronary angiography
were published in 1999 but not updated, and they are now
superseded by the above documents.
There are no high-quality data on which to base rec-
ommendations for performing diagnostic coronary angi-
ography because no study has randomized patients with
SIHD to either catheterization or no catheterization. Tri-
als in patients with SIHD comparing revascularization
and GDMT have, to date, all required angiography,
most often after stress testing, as a prerequisite for subse-
quent revascularization. Additionally, the ‘‘incremental
benefit’’ of detecting or excluding CAD by coronary
angiography remains to be determined. The ISCHEMIA
(International Study of Comparative Health Effectiveness
With Medical and Invasive Approaches) trial is currently
randomizing patients with at least moderate ischemia on
stress testing to a strategy of optimal medical therapy
alone (with coronary angiography reserved for failure
of medical therapy) or routine cardiac catheterization fol-
lowed by revascularization (when appropriate) plus
optimal medical therapy. Before randomization, however,
patients with normal renal function will undergo
‘‘blinded’’ computed tomography (CT) angiography to
exclude them if significant left main CAD or no signifi-
cant CAD is present. The writing group strongly endorses
the ISCHEMIA trial, which will provide contemporary,
high-quality evidence about the optimal strategy for man-
aging patients with nonleft main SIHD and moderate-to-
severe ischemia.
In the majority of patients with suspected SIHD, noninva-
sive stress testing for diagnosis and risk stratification is the
appropriate initial study. Importantly, coronary angiog-
raphy is appropriate only when the information derived
from the procedure will significantly influence patient man-
agement and if the risks and benefits of the procedure have
been carefully considered and understood by the patient.
Coronary angiography to assess coronary anatomy for
revascularization is appropriate only when it is determined
beforehand that the patient is amenable to, and a candidate
for, percutaneous or surgical revascularization. In patients
with abnormal, noninvasive stress testing for whom a diag-
nosis of CAD remains in doubt, many clinicians proceed toe10 The Journal of Thoracic and Cardiovascular Surgdiagnostic coronary angiography. However, in some pa-
tients, multidetector CT angiography may be appropriate
and safer than routine invasive angiography for this pur-
pose. Indications and contraindications to CT angiography,
including subsets of patients for whom it can be considered,
are also discussed in the 2010 expert consensus document
on CT angiography18 and the 2010 appropriate use criteria
for cardiac CT.19
Although coronary angiography is considered the ‘‘gold
standard’’ for the diagnosis of CAD, it has inherent limita-
tions and shortcomings. Angiographic assessment of steno-
sis severity relies on comparison to an adjacent,
nondiseased reference segment. In diffusely diseased coro-
nary arteries, lack of a normal reference segment may lead
to underestimation of lesion severity by angiography. Mul-
tiple studies have documented significant interobserver
variability in the grading of coronary artery stenosis,20,21
with disease severity overestimated by visual assessment
when coronary stenosis is 50%.21,22 Although
quantitative coronary angiography provides a more
accurate assessment of lesion severity than does visual
assessment, it is rarely used in clinical practice because it
does not accurately assess the physiological significance
of lesions.23 Many stenoses considered to be severe by vi-
sual assessment of coronary angiograms (ie,70% luminal
narrowing) do not restrict coronary blood flow at rest or
with maximal dilatation, whereas others considered to be
‘‘insignificant’’ (ie,<70% luminal narrowing) are hemody-
namically significant.24 Coronary angiography also cannot
assess whether an atherosclerotic plaque is stable or
‘‘vulnerable’’ (ie, likely to rupture and cause an acute coro-
nary syndrome).
Intravascular ultrasound and optical coherence tomogra-
phy provide more precise information about the severity of
stenosis and plaquemorphology than does coronary angiog-
raphy and, in certain cases, can be useful adjunctive tests.9
These imaging procedures are discussed in the 2011 PCI
guideline.9 FFR can assess the hemodynamic significance
of angiographically ‘‘intermediate’’ or ‘‘indeterminant’’ le-
sions and allows one to decide when PCI may be beneficial
or safely deferred.24,25 It has been suggested in several
studies that a PCI strategy guided by FFR may be
superior to a strategy guided by angiography alone.5,24,26,27
Invasive procedures may cause complications. Data from
the ACC’s National Cardiovascular Data Registry CathPCI
Registry during the 2012 calendar year included a 1.5%
incidence of procedural complications of diagnostic angi-
ography. Complications in earlier reports included death,
stroke, myocardial infarction (MI), bleeding, infection,
contrast allergic or anaphylactoid reactions, vascular dam-
age, contrast-induced nephropathy, arrhythmias, and need
for emergency revascularization.28-32 Complications are
more likely to occur in certain patient groups, including
those of advanced age (>70 years), and those withery c March 2015
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Society class IV angina or New York Heart Association
class IV heart failure), severe left ventricular dysfunction
or CAD (particularly left main disease), severe valvular
disease, severe comorbid medical conditions (eg, renal,
hepatic, or pulmonary disease), bleeding disorders, or a
history of an allergic reaction to radiographic contrast
material.28-32 The risk of contrast-induced nephropathy is
increased in patients with renal insufficiency or diabetes
mellitus.9,33 In deciding whether angiography should be
performed in these patients, these risks should be
balanced against the increased likelihood of finding
critical CAD. The concept of informed consent requires
that risks and benefits of and alternatives to coronary
angiography be explicitly discussed with the patient
before the procedure is undertaken.
Despite these shortcomings and potential complications,
coronary angiography is useful to a) ascertain the cause of
chest pain or anginal equivalent symptoms, b) define coro-
nary anatomy in patients with ‘‘high-risk’’ noninvasive
stress test findings (Section 3.3 in the 2012 full-text guide-
line) as a requisite for revascularization, c) determine
whether severe CAD may be the cause of depressed left
ventricular ejection fraction, d) assess for possible
ischemia-mediated ventricular arrhythmia, e) evaluate car-
diovascular risk among certain recipient and donor candi-
dates for solid-organ transplantation, and f) assess the
suitability for revascularization of patients with unaccept-
able ischemic symptoms (ie, symptoms that are not
controlled with medication and that limit activity or quality
of life). Coronary angiography may also be helpful when
initial stress testing is inconclusive or yields conflicting re-
sults and definitive determination of whether IHD is present
will result in important changes to therapy. The exclusion of
epicardial CAD in a patient with recurring chest pain or
other potential ischemic symptoms is particularly useful
when it leads to more appropriate treatment, including with-
drawal of medications.
In a subset of patients, clinical characteristics, symp-
toms, and/or results of noninvasive testing alone indicating
a high likelihood of multivessel or left main disease (eg,
large ischemic burden) may prompt diagnostic angiog-
raphy and revascularization, instead of initial stress testing.
Patients with long-standing diabetes mellitus and end-
organ damage, severe peripheral vascular disease (eg,
abdominal aortic aneurysm), or previous chest (mantle)
radiation therapy may have severe CAD—particularly
when ischemic symptoms are present.28-31 Patients with
a combination of typical angina, transient heart failure,
pulmonary edema, or exertional or unheralded syncope
may have severe CAD. Noninvasive testing, such as rest
echocardiography revealing multiple regional wall
motion abnormalities or electrocardiography with diffuse
ischemic changes in multiple territories, may reflectThe Journal of Thoracic and CaCAD with a large ischemic burden and justify diagnostic
angiography without prior stress testing. The writing
group has found that creating a recommendation
governing the use of angiography for such high-risk pa-
tients remains controversial. The writing group recognizes,
however, that many clinicians believe that prompt
diagnostic angiography and revascularization, instead of
initial stress testing, are appropriate for such high-risk
patients who are likely to have underlying severe CAD
for which revascularization would confer a survival
advantage.
Coronary angiography is not routinely performed after
adequate stress testing has been negative for ischemia. Still,
stress tests can be falsely negative and, in a patient with high
pretest likelihood of CAD, Bayes’ theorem predicts that a
high post-test likelihood of CADwill remain as well. There-
fore, when clinicians strongly suspect that a stress test is
falsely negative (eg, a patient with typical angina who
also has multiple risk factors for CAD), diagnostic angiog-
raphy may be warranted. When stress testing yields an
ambiguous or indeterminate result in a patient with a high
likelihood of CAD, coronary angiography may be prefer-
able to another noninvasive test and may be the most effec-
tive means to reach a diagnosis.
The frequency with which coronary angiography is per-
formed varies across geographic regions, and in some areas
it may be underutilized or overutilized.34 The optimal rate
of ‘‘normal’’ coronary angiography in clinical practice re-
mains undefined. In the ACC’s National Cardiovascular
Data Registry CathPCI Registry, approximately 45% of
elective cardiac catheterizations performed at hospitals
did not detect clinically significant (defined as >50%
luminal diameter) stenoses,29,35 although rates varied
markedly between hospitals (ie, range, 0% to 77%).35 Hos-
pitals with lower rates of significant CAD at catheterization
were more likely to have performed angiography on
younger patients; thosewith no symptoms or atypical symp-
toms; and those with negative, equivocal, or unperformed
functional status assessment.35 Even among those with a
positive result on a noninvasive test, only 41% of patients
were found to have significant CAD.36 In a study performed
within the Veterans Health Administration, 21% of patients
undergoing elective catheterization had ‘‘normal’’ coronary
arteries (defined as having no lesions 20%). The median
proportion of normal coronary arteries was 10.8% among
hospitals in the lowest quartile and 30.3% among hospitals
in the highest quartile.37 The authors concluded that factors
causing variation in patient selection for coronary angiog-
raphy exist in integrated non–fee-for-service health systems
as well as in fee-for-service systems.
Angiographically normal or near-normal coronary ar-
teries are more common among women, who are more
likely than men to have myocardial ischemia due to micro-
vascular disease. The relatively high proportion of patientsrdiovascular Surgery c Volume 149, Number 3 e11
Clinical Guidelines Fihn et alwith ischemia and no significant epicardial stenoses may
indicate opportunities to improve patient selection for
coronary angiography, or to consider the possibility of syn-
dromes caused by abnormal coronary vasoreactivity. Never-
theless, the exclusion of significant epicardial CAD with a
high level of confidence can be important for high-quality
diagnosis and patient management, and therefore the re-
ported frequencies of normal coronary findings should be
understood within this context.29,35-373. TREATMENT
3.1. Guideline-Directed Medical Therapy
3.1.1. Additional Medical Therapy to Prevent MI and
Death: Recommendation
3.1.1.1. Additional Therapy to Reduce Risk of MI and Death
See Table 2 for the revised recommendation for chelation
therapy and Online Data Supplement 2 for evidence
supporting the recommendation.
3.1.1.1.1. Chelation Therapy. Chelation therapy, which
consists of a series of intravenous infusions of disodium
ethylene diamine tetraacetic acid (EDTA) in combination
with other substances, has been touted as a putative noninva-
sive means of improving blood flow in atherosclerotic ves-
sels, treating angina, and preventing cardiac events. EDTA
combines with polyvalent cations, such as calcium and cad-
mium (a constituent of cigarette smoke that is associated
with cardiovascular risk),43,44 to form soluble complexes
that can be excreted. Advocates maintain that this process
can result in both regression of atherosclerotic plaques and
relief of angina and that EDTA reduces oxidative stress in
the vascular wall. Anecdotal reports have suggested that
EDTA chelation therapy can result in relief of angina in
patients with SIHD. Studies in patients with intermittent
claudication and SIHD have failed to demonstrate
improvements in exercise measures,38,39 ankle-brachial in-
dex,38,39 or digital subtraction angiograms with
chelation.40A randomized controlled trial (RCT) examining
the effect of chelation therapy on SIHD studied 84 patients
with stable angina and a positive treadmill test for
ischemia.41 Those randomized to active therapy received
weight-adjusted disodium EDTA chelation therapy for 3
hours per treatment, twice weekly for 15 weeks, and then
once monthly for an additional 3 months. There were no dif-
ferences between groups in changes in exercise time to
ischemia, exercise capacity, or quality-of-life scores. The
National Center of Complementary and Alternative Medi-
cine and the National Heart, Lung, and Blood Institute con-
ductedTACT (Trial toAssess Chelation Therapy),42 anRCT
comparing chelation with placebo in patients who had expe-
riencedMI. The primary composite endpoint of totalmortal-
ity, recurrent MI, stroke, coronary revascularization, ore12 The Journal of Thoracic and Cardiovascular Surghospitalization for angina occurred in 222 (26%) patients
in the chelation group and 261 (30%) patients in the pla-
cebo group (hazard ratio: 0.82; 95% CI: 0.69 to 0.99;
P ¼ .035 [because of multiple comparisons, statistical sig-
nificance was considered at P values .036]). No individ-
ual endpoint differed significantly between groups.
Among patients with diabetes mellitus, there was a 39%
reduction (hazard ratio: 0.61; 95% CI: 0.45 to 0.83) in
the composite endpoint for the chelation-treated patients
relative to the placebo-treated patients (P ¼ .02 for inter-
action). Despite these positive findings, the TACT investi-
gators did not recommend the routine use of chelation
therapy to reduce symptoms or cardiovascular complica-
tions for all patients with SIHD, given the modest overall
benefit, high proportion of patient withdrawals (18% lost
to follow-up), absence of adequate scientific basis for the
therapy, and possibility of a false positive outcome. The
large proportion of withdrawals was especially concerning
given that 50% more patients withdrew from chelation
therapy than from placebo, which raised important con-
cerns about unmasking of treatment assignments that
could have influenced key outcomes (eg, revascularization
or hospitalization for angina). In addition, chelation ther-
apy is not risk free. Disodium EDTA, particularly when
infused too rapidly, may cause hypocalcemia, renal fail-
ure, and death.45,46 Although disodium EDTA is
approved by the U.S. Food and Drug Administration for
specific indications, such as iron overload and lead
poisoning, it is not approved for use in preventing or
treating cardiovascular disease. Accordingly, the writing
group finds that the usefulness of chelation therapy in
cardiac disease is highly questionable.
3.1.2. Alternative Therapies for Relief of Symptoms in
Patients With Refractory Angina: Recommendation
See Table 3 for the recommendation on enhanced
external counterpulsation (EECP) and Online Data
Supplement 3 for evidence supporting the recommendation.
3.1.2.1. Enhanced External Counterpulsation. Although
EECP was carefully reviewed in the 2012 SIHD guideline,4
comments received after the guideline’s publication promp-
ted a re-examination of the existing literature, even though
no truly new data have become available. EECP is a tech-
nique that uses inflatable cuffs wrapped around the lower
extremities to increase venous return and augment diastolic
blood pressure.47 The cuffs are inflated sequentially from
the calves to the thigh muscles during diastole and are
deflated instantaneously during systole. The resultant dia-
stolic augmentation increases coronary perfusion pressure,
and the systolic cuff depression decreases peripheral resis-
tance. Treatment is associated with improved left ventricu-
lar diastolic filling, peripheral flow-mediated dilation, and
endothelial function. Other putative mechanisms forery c March 2015
TABLE 2. Recommendation for chelation therapy
2012 Recommendation 2014 Focused update recommendation Comment
Class III: No Benefit
1. Chelation therapy is not recommended with
the intent of improving symptoms or reducing
cardiovascular risk in patients with SIHD.38-41
(Level of Evidence: C)
Class IIb
1. The usefulness of chelation therapy is
uncertain for reducing cardiovascular events
in patients with SIHD.38-42
(Level of Evidence: B)
Modified recommendation (changed Class of
Recommendation from III: No Benefit to IIb
and Level of Evidence from C to B).
SIHD, Stable ischemic heart disease.
Fihn et al Clinical Guidelinesimprovement in symptoms include recruitment of
collaterals, attenuation of oxidative stress and proinflamma-
tory cytokines, promotion of angiogenesis and vasculogen-
esis, and a peripheral training effect.48-51 EECP was
approved by the U.S. Food and Drug Administration in
1995 for the treatment of patients with CAD and
refractory angina pectoris who fail to respond to
standard revascularization procedures and aggressive
pharmacotherapy. A treatment course typically consists of
35 sessions of 1 hour each, given 5 days a week.
Contraindications include decompensated heart failure,
severe peripheral artery disease, and severe aortic
regurgitation.
The efficacy of EECP in treating stable angina pectoris
has been evaluated in 2 RCTs and several observational
registry studies. In MUST-EECP (Multicenter Study of
Enhanced External Counterpulsation), 139 patients with
angina, documented CAD, and evidence of ischemia on
exercise testing were randomized to 35 hours of active
counterpulsation or to inactive counterpulsation (with
insufficient pressure to alter blood pressure).47 Time to
1-mm ST-segment depression on stress testing increased
significantly in patients treated with active counterpulsa-
tion (from 337  18 s to 379  18 s) compared with pla-
cebo (from 326  21 s to 330  20 s; P ¼ .01). The
groups did not differ in terms of exercise duration, change
in daily nitroglycerin use, or mean frequency of angina,
although the percentage reduction in frequency of anginal
episodes was somewhat greater among patients who
received active counterpulsation. Of patients receiving
EECP, 55% reported adverse events, including leg and
back pain and skin abrasions, compared with 26% in
the control group (relative risk: 2.13; 95% CI: 1.35 to
3.38), with approximately half of these events categorized
as device related. An additional trial of EECP wasTABLE 3. Recommendation for EECP
2012 Recommendation 2014 Focused u
Class IIb
1. EECP may be considered for relief of refractory
angina in patients with SIHD.47 (Level of
Evidence: B)
Class IIb
1. EECP may be cons
angina in patients w
Evidence: B)
EECP, Enhanced external counterpulsation; SIHD, stable ischemic heart disease.
The Journal of Thoracic and Caconducted in 42 symptomatic patients with CAD who
were randomized (2:1 ratio) to 35 hours of either EECP
(n ¼ 28) or sham EECP (n ¼ 14).51 Over the 7-week
study period, average Canadian Cardiovascular Society
angina class improved with EECP as compared with
control (3.16  0.47 to 1.20  0.40 and 2.93  0.26 to
2.93  0.26 in EECP and sham control, respectively;
P< .001). Data from RCTs on long-term outcomes are
lacking.
In a meta-analysis of 13 observational studies that
tracked 949 patients, Canadian Cardiovascular Society
anginal class was improved by 1 class in 86% of
EECP-treated patients (95% CI: 82% to 90%). There
was, however, a high degree of heterogeneity among the
studies, which lessens confidence in the results of the
meta-analysis (Q statistic P ¼ .008).52 The EECP Con-
sortium reported results from 2289 consecutive patients un-
dergoing EECP therapy at 84 participating centers,
including a subgroup of 175 patients from 7 centers who un-
derwent radionuclide perfusion stress tests before and after
therapy.53 Treatment was associated with improved perfu-
sion images and increased exercise duration. Similarly,
the International EECP Registry reported improvement of
1 Canadian Cardiovascular Society angina class in 81%
of patients immediately after the last EECP treatment.54 Im-
provements in health-related quality of life have also been
reported with EECP, but there is limited evidence with
which to determine the duration of the health-related bene-
fits of treatment.55,56
In general, existing data, largely from uncontrolled
studies, suggest a benefit from EECP among patients with
angina refractory to other therapy. Additional data from
well-designed RCTs are needed to better define the role
of this therapeutic strategy in patients with SIHD.57 On
the basis of this re-examination of the literature, thepdate recommendation Comment
idered for relief of refractory
ith SIHD.47 (Level of
2012 recommendation remains current.
rdiovascular Surgery c Volume 149, Number 3 e13
Clinical Guidelines Fihn et alrecommendation about EECP remains unchanged from the
2012 guideline.
4. CAD REVASCULARIZATION
4.1. Revascularization to Improve Survival:
Recommendations
See Table 4 for recommendations on CAD revasculariza-
tion to improve survival and Online Data Supplement 4 for
evidence supporting the recommendations.
4.2. CABG Versus PCI
4.2.1. CABG Versus Drug-Eluting Stents
See Online Data Supplement 5 for additional evidence
table.
Although the results of 10 observational studies
comparing CABG and drug-eluting stent (DES) implanta-
tion have been published,70-79 most of these studies had
short follow-up periods (12 to 24 months). In a meta-
analysis of 24,268 patients with multivessel CAD treated
with CABG or DES80 the incidences of death and MI
were similar for the 2 procedures, but the frequency with
which repeat revascularization was performed was roughly
4 times higher after DES implantation. Only 1 large RCT
comparing CABG and DES implantation has been pub-
lished. The SYNTAX (Synergy Between Percutaneous Cor-
onary Intervention With TAXUS and Cardiac Surgery) trial
randomly assigned 1800 patients (of a total of 4337 who
were screened) to receive DES or CABG.66,81,82 Major
adverse cardiac and cerebrovascular events (MACCE)—a
composite of death, stroke, MI, or repeat revascularization
during the 3 years after randomization—occurred in
20.2% of patients who had received CABG and 28.0% of
those who had undergone DES implantation (P< .001).
The rates of death and stroke were not significantly
different; however, MI (3.6% for CABG, 7.1% for DES)
and repeat revascularization (10.7% for CABG, 19.7%
for DES) were more likely to occur with DES
implantation.82 At 5 years of follow-up,83 MACCE
occurred in 26.9% of patients who had received CABG
and 37.3% of those who had undergone DES implantation
(P<.0001). The combined endpoint of death, stroke, or MI
was also lower in CABG-treated patients than in DES-
treated patients (16.7% vs 20.8%; P ¼ .03).83
In SYNTAX, the extent of CAD was assessed using the
SYNTAX score, which is based on the location, severity,
and extent of coronary stenoses, with a low score indicating
less complicated anatomic CAD. In post hoc analyses, a low
score was defined as 22; intermediate, 23 to 32; and high,
33. The occurrence of MACCE correlated with the SYN-
TAX score for DES patients but not for those who had un-
dergone CABG. At 12-month follow-up, the primary
endpoint was similar for CABG and DES in those with ae14 The Journal of Thoracic and Cardiovascular Surglow SYNTAX score. In contrast, MACCE occurred more
often after DES implantation than after CABG in those
with an intermediate or high SYNTAX score.66 At 3 years
of follow-up, the mortality rate was greater in subjects
with 3-vessel CAD treated with DES than in those treated
with CABG (6.2% vs 2.9%). The differences in MACCE
at 5-year follow-up between those treated with DES or
CABG increased with an increasing SYNTAX score.83
Although the utility of the SYNTAX score in everyday
clinical practice remains uncertain, it seems reasonable to
conclude from SYNTAX and other data that survival rates
of patients undergoing PCI or CABG with relatively un-
complicated and lesser degrees of CAD are comparable,
whereas for those with complex and diffuse CAD, CABG
appears to be preferable.81-83
4.2.2. Studies Comparing PCI and CABG for Left Main
CAD
See 2012 SIHDGuideline Data Supplement (Tables 8-13)
for informational evidence tables.4
Of all patients undergoing coronary angiography,
approximately 4% are found to have left main CAD,84
>80% of whom also have significant (70% diameter)
stenoses in other epicardial coronary arteries. In published
cohort studies, it has been found that major clinical
outcomes 1 year after revascularization are similar with
PCI or CABG and that mortality rates are similar at 1, 2,
and 5 years of follow-up; however, the risk of undergoing
target-vessel revascularization is significantly higher with
stenting than with CABG.
In the SYNTAX trial, 45% of screened patients with
unprotected left main CAD had complex disease that pre-
vented randomization; 89% of those underwent
CABG.66,81 In addition, 705 of the 1800 patients with
unprotected left main CAD were randomized to either
DES or CABG. The majority of patients with left main
CAD and a low SYNTAX score had isolated left main
CAD or left main CAD plus 1-vessel CAD. The majority
of those with an intermediate score had left main CAD
plus 2-vessel CAD, and most of those with a high SYN-
TAX score had left main CAD plus 3-vessel CAD. At 1
year, rates of all-cause death and MACCE were similar
among patients who had undergone DES and those who
had undergone CABG.81 Repeat revascularization was
performed more often in the DES group than in the
CABG group (11.8% vs 6.5%), but stroke occurred
more often in the CABG group (2.7% vs 0.3%). At 3
years of follow-up, the incidence of death in those under-
going left main CAD revascularization with low or inter-
mediate SYNTAX scores (<33) was 3.7% after DES
and 9.1% after CABG (P ¼ .03), whereas in those with
a high SYNTAX score (33), the incidence of death after
3 years was 13.4% after DES and 7.6% after CABGery c March 2015
TABLE 4. Recommendations for CAD revascularization to improve survival
2012 Recommendation 2014 Focused update recommendations Comments
Class IIa
1. CABG is probably recommended in
preference to PCI to improve survival in
patients with multivessel CAD and diabetes
mellitus, particularly if a LIMA graft can be
anastomosed to the LAD artery.58-65 (Level of
Evidence: B)
Class I
1. AHeart Team approach to revascularization is
recommended in patients with diabetes
mellitus and complex multivessel CAD.66
(Level of Evidence: C)
2. CABG is generally recommended in
preference to PCI to improve survival in
patients with diabetes mellitus and
multivessel CAD for which revascularization
is likely to improve survival (3-vessel CAD or
complex 2-vessel CAD involving the
proximal LAD), particularly if a LIMA graft
can be anastomosed to the LAD artery,
provided the patient is a good candidate for
surgery.58,61-65,59-69 (Level of Evidence: B)
New recommendation
Modified recommendation (Class of
Recommendation changed from IIa to I,
wording modified, additional RCT added).
CABG, Coronary artery bypass graft;CAD, coronary artery disease; LAD, left anterior descending; LIMA, left internal mammary artery; PCI, percutaneous coronary intervention;
RCT, randomized controlled trial.
Fihn et al Clinical Guidelines(P ¼ .10).81 Because the primary endpoint of the overall
SYNTAX trial was not met (ie, noninferiority comparison
of CABG and DES), the results of these subgroup analyses
need to be applied with caution. At 5 years of follow-up,
MACCE rates did not differ significantly between groups
of patients with low or intermediate SYNTAX scores,
but significantly more patients in the DES group with
high SYNTAX scores had MACCE than in the CABG
group (46.5% vs 29.7%; P ¼ .003).86
In the LEMANS (Study of Unprotected Left Main Stent-
ing Vs Bypass Surgery) trial87, 105 patients with left main
CAD were randomized to receive PCI or CABG. Although
a low proportion of patients treated with PCI received DES
(35%) and a low proportion of patients treated with CABG
received internal mammary grafts (72%), the outcomes at
30 days and 1 year were similar between the groups. In
the PRECOMBAT (Premier of Randomized Comparison
of Bypass Surgery Vs Angioplasty Using Sirolimus-
Eluting Stent in Patients With Left Main Coronary Artery
Disease) trial of 600 patients with left main disease, the
composite endpoint of death, MI, or stroke at 2 years
occurred in 4.4% of patients treated with DES and 4.7%
of patients treated with CABG, but ischemia-driven
target-vessel revascularization was required more often in
the patients treated with PCI (9.0% vs 4.2%).88
The results from these 3 RCTs suggest (but do not defini-
tively prove) thatmajor clinical outcomes in selectedpatients
with left main CAD are similar with CABG and PCI at 1- to
2-year follow-up but that repeat revascularization rates are
higher after PCI than after CABG. RCTs with extended
follow-up of5 years are required to provide definitive con-
clusions about the optimal treatment of left main CAD; 2
such studies are under way. In a meta-analysis of 8 cohort
studies and 2 RCTs,89 death, MI, and stroke occurred withThe Journal of Thoracic and Casimilar frequency in the PCI- and CABG-treated patients at
1, 2, and 3 years of follow-up. Target-vessel revasculariza-
tion was performed more often in the PCI group at 1 year
(OR: 4.36), 2 years (OR: 4.20), and 3 years (OR: 3.30).
Additional analyses using Bayesian methods, initiated by
the Task Force, have affirmed the equivalence of PCI and
CABG for improving survival in patients with unprotected
left main CAD who are candidates for either strategy.12 A
Bayesian cross-design and network meta-analysis was
applied to 12 studies (4 RCTs and 8 observational studies)
comparing CABG with PCI (n ¼; 4574 patients) and to 7
studies (2 RCTs and 5 observational studies) comparing
CABG with medical therapy (n ¼; 3224 patients). The
ORs of death at 1 year after PCI compared with CABG
did not differ among RCTs (OR: 0.99; 95% Bayesian cred-
ible interval 0.67 to 1.43), matched cohort studies (OR:
1.10; 95% Bayesian credible interval 0.76 to 1.73), and
other types of cohort studies (OR: 0.93; 95% Bayesian
credible interval 0.58 to 1.35). A network meta-analysis
suggested that medical therapy is associated with higher
risk of death at 1 year than is the use of PCI for patients
with unprotected left main CAD (OR: 3.22; 95% Bayesian
credible interval 1.96 to 5.30).12 In that study, the Bayesian
method generated a credible interval that has a high proba-
bility of containing the true OR. In other words, the true
value for the OR has a 95% probability of lying within
the interval of 0.68 to 1.45. Because the value 1 is included
in the credible interval, which is also symmetrical, the re-
sults show no evidence of a difference between PCI and
CABG for 1-year mortality rate. The possibility that PCI
is associated with increased or decreased 1-year mortality
over CABG is small (<2.5% for a possible 45% increase
or for a 32% decrease, according to the definition of the
95% Bayesian credible interval).rdiovascular Surgery c Volume 149, Number 3 e15
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In addition to patients’ coronary anatomy, left ventricular
function, and history of prior revascularization, clinical fea-
tures such as the existence of coexisting chronic conditions
might influence decision making. However, the paucity of
information about special subgroups is one of the greatest
challenges in developing evidence-based guidelines appli-
cable to large populations. As is the case for many chronic
conditions, studies specifically geared toward answering
clinical questions about the management of SIHD in
women, older adults, and persons with chronic kidney
disease are lacking. The ‘‘ACCF/AHA guidelines for the
management of patients with unstable angina/non–ST-
elevation myocardial infarction’’90,91 address special
subgroups. The present section echoes those management
recommendations. Although this section will briefly
review some special considerations for diagnosis and
therapy in certain groups of patients, the general approach
should be to apply the recommendations in this guideline
consistently among groups.
4.3.1. Diabetes Mellitus
See Online Data Supplement 6 for additional evidence
table.
In the FREEDOM (Future Revascularization Evaluation
in Patients With Diabetes Mellitus: Optimal Management
of Multivessel Disease) trial, 1900 patients with multivessel
CAD were randomized to either PCI with DES or CABG.68
Theprimary outcome—acomposite of death, nonfatalMI, or
nonfatal stroke—occurred less frequently in the CABG
group (P ¼ .005), with 5-year rates of 18.7% in the CABG
group and 26.6% in the DES group. The benefit of CABG
was related to differences in rates of both MI (P< .001)
and death from any cause (P ¼ .049). Stroke was more
frequent in the CABG group, with 5-year rates of 5.2% in
the CABG group and 2.4% in the DES group (P ¼ .03).
Other studies have providedmixed evidence, but none has
suggested a survival advantage of PCI. The 5-year update
from the SYNTAX trial did not show a significant advantage
in survival after CABG compared with survival after DES in
patients with diabetesmellitus andmultivessel CAD (12.9%
vs 19.5%;P¼ .065).83Ameta-analysis of 4 trials showed no
significant advantage in survival after CABG compared with
survival after PCI for patients with diabetes mellitus (7.9%
vs 12.4%; P ¼ .09).92 In a pooled analysis, it was found
that patients with diabetes mellitus assigned to CABG had
improved survival (23%vs 29%;P¼ .008 for the interaction
betweenpresence of diabetesmellitus and type of revascular-
ization procedure after adjustment).93
The strongest evidence supporting the use of CABG over
PCI for patients with diabetes mellitus and multivessel
CAD comes from a published meta-analysis of 8 trials
(including FREEDOM).68 The study of 3131 patients
showed that at 5-year or longest follow-up, patients withe16 The Journal of Thoracic and Cardiovascular Surgdiabetes mellitus randomized to CABG had a lower all-
cause mortality rate than did those randomized to PCI
with either DES or bare metal stent (relative risk 0.67;
95% CI: 0.52 to 0.86; P ¼ .002).94
In summary, patients with SIHD and diabetes mellitus
should receive GDMT. For patients whose symptoms
compromise their quality of life, revascularization should
be considered. CABG appears to be associated with lower
risk of mortality than is PCI in most patients with diabetes
mellitus and complex multivessel disease, although the
Heart Team may identify exceptions. To address the impor-
tant issue of deciding between PCI and CABG in patients
with diabetes mellitus and complex multivessel CAD, a
Heart Team approach would be beneficial. This was an in-
tegral component of the FREEDOM, SYNTAX, and
BARI trials68,66,59 and is therefore emphasized in this
setting. The Heart Team is a multidisciplinary team
composed of an interventional cardiologist and a cardiac
surgeon who jointly 1) review the patient’s medical
condition and coronary anatomy, 2) determine that PCI
and/or CABG are technically feasible and reasonable,
and, 3) discusses revascularization options with the
patient before a treatment strategy is selected.
Future research may be facilitated by including a field in
the National Cardiovascular Data PCI Registry and the STS
database to identify cases ‘‘turned down’’ for the alternative
revascularization strategy.
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